

Michigan Department of Corrections

REPORT TO THE LEGISLATURE

Pursuant to P.A. 87 of 2021

Article 2, Section 405

Substance Abuse Reporting Requirements

Sec. 405. *By March 1, the department shall report to the senate and house appropriations subcommittees on corrections, the senate and house fiscal agencies, the legislative corrections ombudsman, and the state budget office on the number of prisoners who received medication assisted therapies, the length of time on therapies, and the number of prisoners who have discontinued treatment while incarcerated.*

Beginning in 2017, the Michigan Department of Corrections began providing Medications for Addiction Treatment, specifically Vivitrol, to individuals that were paroling with an opioid or alcohol use disorder. The department started planning for an expansion of services in 2018 to include the use of buprenorphine and naltrexone products and prescribing them during the length of an individual's incarceration. The first prescriptions for these medications began in FY 2020.

The department prescribed buprenorphine (generic Suboxone or Sublocade) or oral naltrexone for 394 individuals, the length of time they have been on medications is:

Buprenorphine/Naloxone: 380 Naltrexone (oral): 14 Total: 394		Released	Active
	Less than 30 days:	38	0
	30-90 days:	27	0
	91-180 days:	35	35
	181-270 days:	0	96
	271-365 days:	0	108
	365+ days:	0	55
	TOTAL:	100	294

Discontinued treatment while incarcerated: 4